El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
Español (Latinoamérica)
Medtronic PLC
Cerrado
SectorSalud
87.07 -0.51
Resumen
Variación precio
24h
Mínimo
86.71
Máximo
87.4
Ingresos | -231M 1.1B |
|---|---|
Ventas | 57M 9B |
P/B Media del Sector | 25.514 61.417 |
BPA | 1.36 |
Rentabilidad por dividendo | 3.11 |
Margen de beneficio | 12.675 |
Empleados | 95,000 |
EBITDA | 124M 2.5B |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 meses | +30.92% upside |
Rentabilidad por dividendo Media del Sector | 3.11% 2.40% |
|---|---|
Próximas Ganancias | 20 may 2026 |
Fecha Próximo Dividendo | 17 abr 2026 |
Próxima Fecha de Ex Dividendo | 27 mar 2026 |
Capitalización de Mercado | -10B 117B |
|---|---|
Apertura anterior | 87.58 |
Cierre anterior | 87.07 |
Noticias sobre sentimiento de mercado
By Acuity
16%
84%
13 / 351 Clasificación en Healthcare
Puntuación técnica
By Trading Central
Confianza
Weak Bearish Evidence
Medtronic PLC Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Medtronic PLC Esperado
Precio Objetivo
By TipRanks
30.92% repunte
Estimación a 12 meses
Media 114.08 USD 30.92%
Máximo 125 USD
Mínimo 100 USD
De acuerdo con 17 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Medtronic PLC Dist en los últimos 3 meses.
Sentimiento
By Acuity
13 / 351 Clasificación en Salud
Noticias sobre sentimiento de mercado
Coyuntura alcista notoria
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por debajo de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Medtronic PLC
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.
Live chat